NAD+ Oral Supplement Pilot Intervention in Adult Females
NCT ID: NCT06579209
Last Updated: 2025-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2024-12-01
2025-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Will executive function change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving the NAD+ to see if the results differ from those receiving the placebo.
Participants will:
Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
NCT06505967
Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)
NCT03707652
Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
NCT05517122
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease
NCT03579693
Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort
NCT07336836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pre-testing prior to intervention
Prior to receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
No interventions assigned to this group
Post-testing after intervention
After receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
No interventions assigned to this group
Intervention
For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.
Nicotinamide adenine dinucleotide
Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide adenine dinucleotide
Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
80 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of General Medical Sciences (NIGMS)
NIH
University of Rhode Island
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rhode Island
Kingston, Rhode Island, United States
Independence Square, University of Rhode Island
Pawtucket, Rhode Island, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Geoff Greene, Ph.D.
Role: backup
Geoff Greene, Ph.D.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2087241-4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.